Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Liangdan Sun is currently navigating the patent prosecution process in the Biotechnology & Pharmaceuticals technology area. The portfolio has 2 pending office actions. These actions are distributed across 2 distinct examiners and 2 distinct art units, indicating a more diversified prosecution landscape than portfolios with a single pending matter.
The busiest examiner for this portfolio is HAVLIN, ROBERT H, who is managing 1 pending office action. This means that the 2 pending office actions are split among multiple officials. The involvement of 2 distinct art units suggests that the technology may span different sub-sectors within the Biotechnology & Pharmaceuticals field, requiring varied technical expertise from the patent office.
With 2 distinct examiners, there is an opportunity to observe different examination styles. However, since the busiest examiner pending count is 1, no single examiner dominates the current workload. The prosecution strategy must account for the standards of multiple art units, which provides a broader base of interaction with the patent office than a single-unit portfolio, allowing for a more comparative analysis of procedural tendencies.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAVLIN, ROBERT H | 1 | 51.3% | +28.3% |
| STRIEGEL, THEODORE CHARLES | 1 | 21.9% | +23.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18081983 | APPLICATION OF ADRB1 ACTIVE INHIBITOR IN PREPARING PREPARATION OR AS PREPARATION FOR TREATING PSORIASIS | HAVLIN, ROBERT H | 78d |
| 17564737 | EVALUATION SYSTEM FOR EVALUATING PSORIASIS AND USE THEREOF | STRIEGEL, THEODORE CHARLES | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18081983 | APPLICATION OF ADRB1 ACTIVE INHIBITOR IN PREPARING PREPARATION OR AS PREPARATION FOR TREATING PSORIASIS | HAVLIN, ROBERT H | 78d |
| 17564737 | EVALUATION SYSTEM FOR EVALUATING PSORIASIS AND USE THEREOF | STRIEGEL, THEODORE CHARLES | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| 1685 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18081983 | APPLICATION OF ADRB1 ACTIVE INHIBITOR IN PREPARING PREPARATION OR AS PREPARATION FOR TREATING PSORIASIS | HAVLIN, ROBERT H | 1626 | §103§112 | Final Rejection | 78d | Pending | Dec 15, 2022 |
| 17564737 | EVALUATION SYSTEM FOR EVALUATING PSORIASIS AND USE THEREOF | STRIEGEL, THEODORE CHARLES | 1685 | §101§112 | Final Rejection | — | Pending | Dec 29, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLiangdan Sun has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Robert H Havlin has the most, with 1 of Liangdan Sun's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
